RxDoctor Payments Data

Thomas Howard

Pediatric Hematology-Oncology · Birmingham, ALNPI 1336252436

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $479 of the $767 with a category attached, or 62.5%. Novartis accounts for 96.4% of it on its own, with 1 other manufacturer making up the rest.

$767in general payments, 2019–2025

Across 6 payments — averaging $127.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$739
  • Exelixis Inc.$27
$591,918in research payments, 2019–2025

Across 12 payments — averaging $49,326 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$551K
  • Global Blood Therapeutics, Inc.$40K

What the payments were for

  • Travel & lodging$47963%
  • Food & beverage$28737%

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis5$739
Exelixis Inc.1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 60th percentile of 38 pediatric hematology-oncology providers in Alabama.

See all pediatric hematology-oncology providers in Alabama

Other pediatric hematology-oncology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →